Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Inactive)
Company: Annovis Bio, TorreyPines Therapeutics, Inc.
Phenserine is a physostigmine analog that inhibits acetylcholinesterase. It has also been shown to inhibit Aβ production by reducing expression of APP (Klein, 2007; Venti et al., 2004; Utsuki et al., 2006).
Phenserine’s development was stopped after it failed to improve cognition or clinical measures in two Phase 3 trials (Sep 2005 news).
- Klein J. Phenserine. Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. PubMed.
- Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, Rogers JT. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann N Y Acad Sci. 2004 Dec;1035:34-48. PubMed.
- Utsuki T, Yu QS, Davidson D, Chen D, Holloway HW, Brossi A, Sambamurti K, Lahiri DK, Greig NH, Giordano T. Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther. 2006 Aug;318(2):855-62. PubMed.
No Available Further Reading